Figure 4 | Scientific Reports

Figure 4

From: The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

Figure 4

The association of bTMB and CNA combination with clinical outcome of gastric cancer patients treated with nivolumab monotherapy. Kaplan–Meier estimates of progression-free survival (PFS, a), as well as overall survival (OS, b) of patients stratified by the combination of bTMB and CNA in the overall population. Kaplan–Meier estimates of PFS (c), as well as OS (d) of patients stratified by the combination of bTMB and CNA when MSI-H cased excluded. bTMB blood tumor mutation burden, CNA copy number alteration, MSI-H microsatellite instability high.

Back to article page